Denmark: Ensoma closes Twelve Bio acquisition

By
Nick Herbert
-

Ensoma, a genomic medicines company developing one-time in vivo treatments that precisely engineer any cell of the hematopoietic system to cure diseases from within, has closed the acquisition of Twelve Bio, a gene editing company pioneering the therapeutic application of next-generation CRISPR-Cas medicines. In January, Ensoma, raised US$85m in financing to advance the development of its Engenious in…

Membership Required

You must be a HMI Subscriber to view this content.

Subscribe Now »

Already have an account?
Previous articleWalking the talk
Next articleHM meets…Dr Ian Gargan
Nick Herbert
Nick Herbert
Nick Herbert has over 30 years’ experience in the financial markets, as both a practitioner and journalist. He started work as an investment banker in London, before joining International Financing Review (IFR) to report on debt capital markets and derivatives. He moved to Singapore in 2000 to manage IFR’s financial markets editorial team throughout Asia, before returning to London in 2009 to take up the position of Publisher for Reuters Capital Markets Publications. For the last five years he has been covering global capital markets, ESG finance and healthcare markets on a freelance basis.
Linkedin

RELATED ARTICLESMORE FROM AUTHOR